scholarly journals Polymers and Nanoparticles for Statin Delivery: Current Use and Future Perspectives in Cardiovascular Disease

Polymers ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 711
Author(s):  
Antonio Nenna ◽  
Francesco Nappi ◽  
Domenico Larobina ◽  
Emanuele Verghi ◽  
Massimo Chello ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Ischemia Reperfusion Injury ◽  
Ischemia Reperfusion ◽  
Specific Interaction ◽  
Cardiac Regeneration ◽  
Statin Treatment ◽  
Current Evidence ◽  
Vascular Endothelial ◽  
Mortality And Morbidity ◽  
Artery Disease

Atherosclerosis-related coronary artery disease (CAD) is one of the leading sources of mortality and morbidity in the world. Primary and secondary prevention appear crucial to reduce CAD-related complications. In this scenario, statin treatment was shown to be clinically effective in the reduction of adverse events, but systemic administration provides suboptimal results. As an attempt to improve bioavailability and effectiveness, polymers and nanoparticles for statin delivery were recently investigated. Polymers and nanoparticles can help statin delivery and their effects by increasing oral bioavailability or enhancing target-specific interaction, leading to reduced vascular endothelial dysfunction, reduced intimal hyperplasia, reduced ischemia-reperfusion injury, increased cardiac regeneration, positive remodeling in the extracellular matrix, reduced neointimal growth and increased re-endothelization. Moreover, some innovative aspects described in other cardiovascular fields could be translated into the CAD scenario. Recent preclinical studies are underlining the effect of statins in the stimulation and differentiation of endogenous cardiac stem cells, as well as in targeting of local adverse conditions implicated in atherosclerosis, and statin delivery through poly-lactic-co-glycolic acid (PLGA) appears the most promising aspect of current research to enhance drug activity. The present review intends to summarize the current evidence about polymers and nanoparticles for statin delivery in the field of cardiovascular disease, trying to shed light on this topic and identify new avenues for future studies.

scholarly journals Thrombo-Inflammation in Cardiovascular Disease: An Expert Consensus Document from the Third Maastricht Consensus Conference on Thrombosis

2020 ◽  
Vol 120 (04) ◽  
pp. 538-564 ◽  
Author(s):  
Elisa d’Alessandro ◽  
Christian Becker ◽  
Wolfgang Bergmeier ◽  
Christoph Bode ◽  
Joshua H. Bourne ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Ischemia Reperfusion Injury ◽  
Ischemia Reperfusion ◽  
Critical Role ◽  
Consensus Conference ◽  
The Third ◽  
Consensus Document ◽  
Expert Opinions ◽  
Artery Disease ◽  
Expert Consensus Document

AbstractThrombo-inflammation describes the complex interplay between blood coagulation and inflammation that plays a critical role in cardiovascular diseases. The third Maastricht Consensus Conference on Thrombosis assembled basic, translational, and clinical scientists to discuss the origin and potential consequences of thrombo-inflammation in the etiology, diagnostics, and management of patients with cardiovascular disease, including myocardial infarction, stroke, and peripheral artery disease. This article presents a state-of-the-art reflection of expert opinions and consensus recommendations regarding the following topics: (1) challenges of the endothelial cell barrier; (2) circulating cells and thrombo-inflammation, focused on platelets, neutrophils, and neutrophil extracellular traps; (3) procoagulant mechanisms; (4) arterial vascular changes in atherogenesis; attenuating atherosclerosis and ischemia/reperfusion injury; (5) management of patients with arterial vascular disease; and (6) pathogenesis of venous thrombosis and late consequences of venous thromboembolism.

Oral antiplatelet agents in cardiovascular disease

VASA ◽  
2019 ◽  
Vol 48 (4) ◽  
pp. 291-302 ◽  
Author(s):  
Joseph Pultar ◽  
Patricia P. Wadowski ◽  
Simon Panzer ◽  
Thomas Gremmel
Keyword(s):  
Cardiovascular Disease ◽  
Antiplatelet Agent ◽  
Antiplatelet Agents ◽  
Adenosine Diphosphate ◽  
Current Evidence ◽  
Mortality And Morbidity ◽  
Beneficial Effects ◽  
History Of ◽  
Coronary Syndromes ◽  
Artery Disease

Abstract. Antiplatelet agents significantly reduce mortality and morbidity in ischemic heart disease, cerebrovascular disease and peripheral artery disease (PAD), and are therefore part of guideline-driven daily medical treatment in these patients. Due to its beneficial effects in the secondary prevention of atherothrombotic events, aspirin remains the most frequently prescribed antiplatelet agent in cardiovascular disease. In patients with acute coronary syndromes (ACS) and in those undergoing angioplasty with stent implantation dual antiplatelet therapy with aspirin and an adenosine diphosphate (ADP) receptor antagonist is indicated. The development of the newer ADP P2Y12inhibitors prasugrel and ticagrelor has further improved prognosis in ACS patients compared to clopidogrel. Moreover, vorapaxar allows the inhibition of platelet activation by thrombin via protease-activated receptor-1 and has been approved for the use in patients with PAD and in those with a history of myocardial infarction. This review article summarizes the current evidence on oral antiplatelet agents in cardiovascular disease.Keywords: Aspirin, clopidogrel, prasugrel, ticagrelor, vorapaxar, cardiovascular disease

scholarly journals The Diverse Roles of TNNI3K in Cardiac Disease and Potential for Treatment

2021 ◽  
Vol 22 (12) ◽  
pp. 6422
Author(s):  
Caroline Pham ◽  
Noelia Muñoz-Martín ◽  
Elisabeth M. Lodder
Keyword(s):  
Cardiac Disease ◽  
Genetic Variants ◽  
Ischemia Reperfusion Injury ◽  
Ischemia Reperfusion ◽  
Cardiac Regeneration ◽  
Cardiac Diseases ◽  
Supraventricular Arrhythmias ◽  
Clinical Perspective ◽  
Physiological Processes

In the two decades since the discovery of TNNI3K it has been implicated in multiple cardiac phenotypes and physiological processes. TNNI3K is an understudied kinase, which is mainly expressed in the heart. Human genetic variants in TNNI3K are associated with supraventricular arrhythmias, conduction disease, and cardiomyopathy. Furthermore, studies in mice implicate the gene in cardiac hypertrophy, cardiac regeneration, and recovery after ischemia/reperfusion injury. Several new papers on TNNI3K have been published since the last overview, broadening the clinical perspective of TNNI3K variants and our understanding of the underlying molecular biology. We here provide an overview of the role of TNNI3K in cardiomyopathy and arrhythmia covering both a clinical perspective and basic science advancements. In addition, we review the potential of TNNI3K as a target for clinical treatments in different cardiac diseases.

scholarly journals Application of microRNA Database Mining in Biomarker Discovery and Identification of Therapeutic Targets for Complex Disease

2020 ◽  
Vol 4 (1) ◽  
pp. 5
Author(s):  
Jennifer L. Major ◽  
Rushita A. Bagchi ◽  
Julie Pires da Silva
Keyword(s):  
Complex Disease ◽  
Biomarker Discovery ◽  
Ischemia Reperfusion Injury ◽  
Ischemia Reperfusion ◽  
Expression Patterns ◽  
Therapeutic Targets ◽  
Human Diseases ◽  
Mirna Expression Data ◽  
Artery Disease ◽  
Underlying Mechanisms

Over the past two decades, it has become increasingly evident that microRNAs (miRNA) play a major role in human diseases such as cancer and cardiovascular diseases. Moreover, their easy detection in circulation has made them a tantalizing target for biomarkers of disease. This surge in interest has led to the accumulation of a vast amount of miRNA expression data, prediction tools, and repositories. We used the Human microRNA Disease Database (HMDD) to discover miRNAs which shared expression patterns in the related diseases of ischemia/reperfusion injury, coronary artery disease, stroke, and obesity as a model to identify miRNA candidates for biomarker and/or therapeutic intervention in complex human diseases. Our analysis identified a single miRNA, hsa-miR-21, which was casually linked to all four pathologies, and numerous others which have been detected in the circulation in more than one of the diseases. Target analysis revealed that hsa-miR-21 can regulate a number of genes related to inflammation and cell growth/death which are major underlying mechanisms of these related diseases. Our study demonstrates a model for researchers to use HMDD in combination with gene analysis tools to identify miRNAs which could serve as biomarkers and/or therapeutic targets of complex human diseases.

scholarly journals The Role of Estrogen Receptors in Cardiovascular Disease

2020 ◽  
Vol 21 (12) ◽  
pp. 4314 ◽  
Author(s):  
Laila Aryan ◽  
David Younessi ◽  
Michael Zargari ◽  
Somanshu Banerjee ◽  
Jacqueline Agopian ◽  
...  
Keyword(s):  
Heart Failure ◽  
Cardiovascular Disease ◽  
Estrogen Receptor ◽  
Ejection Fraction ◽  
Estrogen Receptors ◽  
Molecular Mechanisms ◽  
Ischemia Reperfusion Injury ◽  
Ischemia Reperfusion ◽  
Vascular Pathology ◽  
Reduced Ejection Fraction

Cardiovascular Diseases (CVDs) are the leading cause of death globally. More than 17 million people die worldwide from CVD per year. There is considerable evidence suggesting that estrogen modulates cardiovascular physiology and function in both health and disease, and that it could potentially serve as a cardioprotective agent. The effects of estrogen on cardiovascular function are mediated by nuclear and membrane estrogen receptors (ERs), including estrogen receptor alpha (ERα), estrogen receptor beta (ERβ), and G-protein-coupled ER (GPR30 or GPER). Receptor binding in turn confers pleiotropic effects through both genomic and non-genomic signaling to maintain cardiovascular homeostasis. Each ER has been implicated in multiple pre-clinical cardiovascular disease models. This review will discuss current reports on the underlying molecular mechanisms of the ERs in regulating vascular pathology, with a special emphasis on hypertension, pulmonary hypertension, and atherosclerosis, as well as in regulating cardiac pathology, with a particular emphasis on ischemia/reperfusion injury, heart failure with reduced ejection fraction, and heart failure with preserved ejection fraction.

scholarly journals Impact of glucose-6-phosphate dehydrogenase deficiency on the pathophysiology of cardiovascular disease

2013 ◽  
Vol 304 (4) ◽  
pp. H491-H500 ◽  
Author(s):  
Peter A. Hecker ◽  
Jane A. Leopold ◽  
Sachin A. Gupte ◽  
Fabio A. Recchia ◽  
William C. Stanley
Keyword(s):  
Cardiovascular Disease ◽  
G6pd Deficiency ◽  
Cholesterol Synthesis ◽  
Ischemia Reperfusion Injury ◽  
Ischemia Reperfusion ◽  
Pressure Overload ◽  
Protective Role ◽  
Pentose Phosphate ◽  
Protective Effects ◽  
Glucose 6 Phosphate Dehydrogenase

Glucose-6-phosphate dehydrogenase (G6PD) catalyzes the rate-determining step in the pentose phosphate pathway and produces NADPH to fuel glutathione recycling. G6PD deficiency is the most common enzyme deficiency in humans and affects over 400 million people worldwide; however, its impact on cardiovascular disease is poorly understood. The glutathione pathway is paramount to antioxidant defense, and G6PD-deficient cells do not cope well with oxidative damage. Limited clinical evidence indicates that G6PD deficiency may be associated with hypertension. However, there are also data to support a protective role of G6PD deficiency in decreasing the risk of heart disease and cardiovascular-associated deaths, perhaps through a decrease in cholesterol synthesis. Studies in G6PD-deficient (G6PDX) mice are mixed and provide evidence for both protective and deleterious effects. G6PD deficiency may provide a protective effect through decreasing cholesterol synthesis, superoxide production, and reductive stress. However, recent studies indicate that G6PDX mice are moderately more susceptible to ventricular dilation in response to myocardial infarction or pressure overload-induced heart failure. Furthermore, G6PDX hearts do not recover as well as nondeficient mice when faced with ischemia-reperfusion injury, and G6PDX mice are susceptible to the development of age-associated cardiac hypertrophy. Overall, the limited available data indicate a complex interplay in which adverse effects of G6PD deficiency may outweigh potential protective effects in the face of cardiac stress. Definitive clinical studies in large populations are needed to determine the effects of G6PD deficiency on the development of cardiovascular disease and subsequent outcomes.

scholarly journals Ankle-Brachial Index as a Predictor for Cardiovascular Disease in Postmenopausal Women

2019 ◽  
Vol 04 (01) ◽  
pp. 015-019
Author(s):  
Lakshmi Lasya Manchikanti ◽  
Madhuri Taranikanti ◽  
Akhila Dronamraju ◽  
Sudha Bala ◽  
Rohith Kumar Guntuka
Keyword(s):  
Cardiovascular Disease ◽  
Cardiovascular Diseases ◽  
Postmenopausal Women ◽  
Heart Diseases ◽  
Ankle Brachial Index ◽  
Digital Data ◽  
Anthropometric Parameters ◽  
Cross Sectional ◽  
Mortality And Morbidity ◽  
Artery Disease

Abstract Background and Aim Menopausal women are at an increasing risk of cardiovascular diseases due to ovarian failure with estrogen deficiency. Redistribution of fat leading to abdominal obesity is a risk factor for cardiovascular disease. Dyslipidemia is one of the risk factors for peripheral artery disease (PAD) and coronary artery disease (CAD). Prevalence of PAD in women is similar or even higher than men, especially after menopause. ankle-brachial index (ABI) is a gold standard technique to diagnose PAD and acts as an independent prognostic marker to identify patients with high cardiovascular risk. This study aims to compare the ABI between pre- and postmenopausal women and to show that routine use of ABI as a screening tool can be valuable in predicting mortality and morbidity from heart diseases in peri- and postmenopausal women. Material and Methods A cross-sectional study was done on a total of 107 women with no prior medical diseases such as hypertension, diabetes mellitus, cardiovascular diseases, and history of smoking. Fifty pre- and 57 postmenopausal women were included in this study. Anthropometric parameters such as height, weight, and body mass index (BMI) were measured. ABI was calculated by measuring the systolic pressures at posterior tibial artery and brachial artery, as per the protocols using digital data acquisition system. Results BMI in postmenopausal women was significantly higher with p = 0.0023. Systolic and diastolic blood pressures were significantly higher in postmenopausal women (p = 0.000001), and ABI was found to be significantly lower in postmenopausal women particularly on the left side. Conclusion ABI serves as an efficient indicator of PAD. It becomes necessary to understand the progression of PAD as its presence can increase the risk of mortality and morbidity from CAD. Early diagnosis of cardiovascular disease through simple techniques such as ABI measurement would provide scope for early interventional strategies.

Sign in / Sign up

Export Citation Format

Share Document